Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1696 to 1710 of 7711 results

  1. Sotagliflozin for treating type 2 diabetes [ID1657]

    Awaiting development [GID-TA10665] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. eXroid for internal haemorrhoids

      Status ...

    Medical technologies guidance
    Topic selection

  3. Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769

    Awaiting development [GID-TA11088] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Respirasense

      Status ...

    Medical technologies guidance
    Topic selection

  5. Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659

    Awaiting development [GID-TA11111] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Macitentant–tadalafil for treating pulmonary arterial hypertension TS ID 10517

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Treprostinil diethanolamine for treating pulmonary arterial hypertension TS ID 11772

    Awaiting development [GID-TA11123] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Nitazoxanide for treating the common cold in people 12 years and over TS ID 10548

    Awaiting development [GID-TA11128] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 TS ID 11778

      Status ...

    Technology appraisal guidance
    Topic selection

  10. CT-P43 (ustekinumab biosimilar) for treating moderate to severe plaque psoriasis TS ID 11773

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TS ID 10574]

      Status ...

    Technology appraisal guidance
    Topic selection

  12. Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

    Awaiting development [GID-TA10694] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]

    Awaiting development [GID-TA10715] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340

    In development [GID-TA10313] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

    Awaiting development [GID-TA10723] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development